| Schedule of Restructuring and Transformation Costs by Type of Cost |
The following table summarizes the activity for restructuring reserves related to prior programs, the 2020 Program, portfolio rationalization initiatives, and market and regional alignment initiatives for the fiscal years 2026, 2025 and 2024, substantially all of which relates to employee severance, other employee costs, inventory reserves and lease termination fees: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Prior Programs | | 2020 Program | | Portfolio Rationalization Initiatives | | Market and Regional Alignment Initiatives | | Total | | (Dollars in Thousands) | | Balance as of April 1, 2023 | $ | 340 | | | $ | 1,810 | | | $ | — | | | $ | — | | | $ | 2,150 | | | Costs incurred, net of reversals | (276) | | | 450 | | | 13,915 | | | — | | | 14,089 | | | Payments | (64) | | | (1,775) | | | (2,606) | | | — | | | (4,445) | | | | | | | | | | | | | Balance as of March 30, 2024 | $ | — | | | $ | 485 | | | $ | 11,309 | | | $ | — | | | $ | 11,794 | | | Costs incurred, net of reversals | — | | | 566 | | | 12,797 | | | 550 | | | 13,913 | | | Payments | — | | | (761) | | | (12,755) | | | (550) | | | (14,066) | | | Non-cash adjustments | — | | | — | | | (8,616) | | | — | | | (8,616) | | | Balance as of March 29, 2025 | $ | — | | | $ | 290 | | | $ | 2,735 | | | $ | — | | | $ | 3,025 | | | Costs incurred, net of reversals | — | | | (62) | | | (1,919) | | | 5,095 | | | 3,114 | | | Payments | — | | | (205) | | | (100) | | | (4,527) | | | (4,832) | | | | | | | | | | | | | Balance as of March 28, 2026 | $ | — | | | $ | 23 | | | $ | 716 | | | $ | 568 | | | $ | 1,307 | |
The following presents the restructuring costs by line item during fiscal 2026, 2025 and 2024 within the Company’s accompanying consolidated statements of income and consolidated statements of comprehensive income: | | | | | | | | | | | | | | | | | | | Year Ended | | 2026 | | 2025 | | 2024 | | (Dollars in Thousands) | | Cost of goods sold | $ | (496) | | | $ | 11,328 | | | $ | 11,286 | | | Research and development | 960 | | | (61) | | | 456 | | | Selling, general and administrative expenses | 2,650 | | | 2,646 | | | 2,347 | | | Total | $ | 3,114 | | | $ | 13,913 | | | $ | 14,089 | |
|
| Restructuring and Related Costs by Segment |
The following presents the restructuring related costs by line item during fiscal 2026, 2025 and 2024 within the Company’s accompanying consolidated statements of income and consolidated statements of comprehensive income: | | | | | | | | | | | | | | | | | | | Year Ended | | 2026 | | 2025 | | 2024 | | (Dollars in Thousands) | | Cost of goods sold | $ | (33) | | | $ | 3,304 | | | $ | 5,734 | | | Research and development | 11 | | | 1,649 | | | 1,750 | | | Selling, general and administrative expenses | 127 | | | 2,292 | | | 2,015 | | | Total | $ | 105 | | | $ | 7,245 | | | $ | 9,499 | |
The tables below present restructuring and restructuring related costs by reportable segment: | | | | | | | | | | | | | | | | | | | Year Ended | | 2026 | | 2025 | | 2024 | | (Dollars in Thousands) | | Restructuring costs | | | | | | | Plasma | $ | 447 | | | $ | 258 | | | $ | 1,015 | | | Blood Center | (558) | | | 4,742 | | | 5,606 | | | Hospital | 1,326 | | | 1,664 | | | 3,863 | | | Corporate | 1,899 | | | 7,249 | | | 3,605 | | | Total | $ | 3,114 | | | $ | 13,913 | | | $ | 14,089 | | | | | | | | | Restructuring related costs | | | | | | | Plasma | $ | 9 | | | $ | 281 | | | $ | 1,050 | | | Blood Center | (1) | | | 154 | | | 286 | | | Hospital | — | | | 143 | | | 408 | | | Corporate | 97 | | | 6,667 | | | 7,755 | | | Total | $ | 105 | | | $ | 7,245 | | | $ | 9,499 | | | | | | | | | Total restructuring and restructuring related costs | $ | 3,219 | | | $ | 21,158 | | | $ | 23,588 | |
|